Objectives: Spasticity is a common and disabling feature of amyotrophic lateral sclerosis (ALS). There are currently no validated ALS-specific measures of spasticity. The aim of this study was to develop and use a self-report outcome measure for spasticity in ALS.
| INTRODUC TI ON
Spasticity is a key feature in amyotrophic lateral sclerosis/motor neurone disease (ALS/MND) and its subtype primary lateral sclerosis. Patients affected by spasticity experience stiffness, spasms and difficulty with fine motor control. Although a predominant symptom of this disease, there is limited information on the epidemiology, clinical characteristics and treatment of spasticity in ALS. Previous research has shown that spasticity may affect ALS patients in distinct ways compared to other neurological disorders. 1 For example, people with ALS may experience recurrent bulbar spasticity which is particularly distressing as breathing and speech are interrupted.
The assessment of the effectiveness of spasticity treatments has been a contentious issue, and gold standard measures are lacking. The Ashworth and modified Ashworth scales are the most widely used clinical methods to assess spasticity but have recently been questioned due to concerns over validity, reliability and responsiveness. 2, 3 Studies have shown that findings on examination performed by a clinician do not always correlate with the patient's symptoms regarding severity and location of spasticity, and there is evidence that the Ashworth scale might not represent the patients' experience of spasticity. 4, 5 For example, as the Ashworth scale is a measure of passive muscle resistance, it cannot be used to assess spasticity-related spasms, which can be severe and debilitating for patients. As a result, there has been a growing interest in developing tools that measure spasticity from patients' perspectives across a variety of neurological conditions, to help clinicians understand and adequately treat spasticity and spasticity-related symptoms.
Patient reported outcome measures (PROMs) such the Multiple Sclerosis Spasticity Scale-88 (MSSS-88), Patient Reported Impact of Spasticity Measure (PRISM) and Leeds Spasticity Scale (LSS) have been validated in MS, spinal cord injury and stroke, respectively.
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To date, no self-report measure of spasticity has been developed for patients with ALS. The aim of this study was to develop a robust and reliable patient reported measure of spasticity for ALS.
| ME THODS
The study comprised qualitative and questionnaire stages to develop and validate the measure, followed by development of a model of spasticity, disability and quality of life. This work was part of the Trajectories of Outcomes in Neurological Conditions (TONiC) study, which is examining factors influencing quality of life over time in several neurological conditions. All participants received written information, and informed consent was obtained prior to enrolment into the study. Ethical approval was granted from the relevant local research committees (reference 11/NW/0743).
| Qualitative stage
Patients with confirmed ALS were invited to take part in one-to-one, semi-structured interviews at the Walton Centre, Liverpool. All patients were assessed for the presence of spasticity by a neurologist (CAY). A purposeful-sampling technique 9 of patients with a wide range of spasticity level and distribution, disability, age and disease duration was employed to ensure that the data obtained at the interviews reflected a comprehensive patient experience of spasticity.
A checklist of topic areas was drawn from extant literature on pa- 
Conclusions:
The SI-ALS is a disease-specific self-report scale, which provides a robust interval-level measure of spasticity in ALS. Spasticity has a substantial impact on quality of life in ALS.
K E Y W O R D S
amyotrophic lateral sclerosis, motor neurone disease, patient reported outcome measures, quality of life, spasticity interviews and the list of themes emerged. The interviews were stopped once theme saturation was achieved. A list of questionnaire items retaining original participants' wording was generated to reflect the main themes and subthemes.
A questionnaire containing 71 items was drafted and subjected to a cognitive debriefing with another set of ALS patients in outpatient clinics. Their feedback was used to modify the format, layout and wording of some of the questions. Expert opinion regarding the content of the questionnaire was also sought from the multidisciplinary team members working with ALS patients including neurologists, rehabilitation consultants, physiotherapists and specialist nurses.
A Likert-style response option with four options of "strongly disagree," "disagree," "agree" and "strongly agree" was chosen. There was an introductory question ("Have you experienced stiffness, tightness, spasms or cramps in any muscles including your legs, arms, trunk, neck and throat in the last 2 weeks?") at the beginning of the scale. If participants answered "No," they were instructed to skip the scale.
| Questionnaire stage
A questionnaire pack containing the 71-item draft together with other measures was mailed to patients with clinically confirmed ALS recruited at thirteen UK neuroscience centres over a 2-year period. Information on demographic characteristics including age, sex, disease type and duration was also collected. For external validation purposes, the following measures were included in the pack:
1. An 11-point numerical rating scale (NRS) for spasticity with anchors of "no spasticity" and "worst possible spasticity in the last 2 weeks." The NRS has been previously validated in epidemiological studies on spasticity in MS. 
Leeds Spasticity Scale (SRSS) Scale for Stroke is an 8-item scale,
which was developed and validated in patients with stroke-related spasticity. 
5.
Patients were asked to report if they suffer from the loss of emotional control (emotional lability).
Non-responders were contacted by phone after 2-4 weeks.
Retest questionnaire was sent to a randomly selected proportion of patients 2 weeks after receiving the first questionnaire. 
| Rasch analysis
The internal validity of the scale was investigated using the Rasch model, a probabilistic measurement model that is now widely used in the health and social sciences. 19 Detailed description of the process of Rasch analysis can be found elsewhere. 20 In summary, Rasch analysis is an iterative process, which tests whether the pattern of responses meets the requirements of the Rasch model. In order for the scale to meet model expectations, the following must be satisfied: Further results of the qualitative study are described elsewhere. 
| Questionnaire stage

| Expert panel and cognitive debriefing
The multidisciplinary panel of clinicians with experience of ALS care endorsed the items as relevant to spasticity. The draft questionnaire was completed face-to-face with a researcher by 17 patients, to ensure the items had face validity and to identify any ambiguities with regard to the instructions, wording and layout.
| Sample characteristics
A total of 465 patients returned the questionnaire packs (response rate 51.6%). The mean age was 64.7 years (SD 10), and 278 (59%)
were male (Table 1) 
| Rasch analysis
Initial fit of the 71-item draft scale to the Rasch model was poor.
A substantial breach of the local independence assumption was (Table 2) .
No differential item functioning was observed for age, gender, marital status, onset type or year of data collection (ANOVA P > .05).
Where any spasticity was reported, the person-item distribution was well targeted, with the mean of persons just below the average of the scale (Figure 1 ).
| Final questionnaire
All three domains identified at the qualitative stage were represented in the final 20-item Spasticity Index-ALS. 
TA B L E 1 Demographic data
Characteristics
| Model
Variables were entered into the model as Rasch-transformed interval scale estimates. A Sobel-Goodman Mediation Test indicated that 27.7% of the effect of spasticity upon quality of life was mediated through motor function, supporting a partial mediation. Adding age into the path model for identification purposes, the path model is shown to be an adequate representation of the data (chi-square 0.97 (df1); P = .3258) (Figure 2 ). All paths were significant with the exception of age at P = .069, showing a trend where increasing age led to 
| D ISCUSS I ON
To authors' knowledge, this is the first study to have investigated ALS patients' experience of spasticity using mixed qualitative and quantitative methods resulting in the development of a patientdriven, interval-level measure of spasticity, which meets the highest standards of psychometric scale development. The SI-ALS comprehensively and accurately reflects patient experience as evaluated in a large cohort with ALS in the UK.
The study demonstrates that spasticity affects the majority of patients with ALS; however, despite its high prevalence there has been a paucity of research on its assessment and treatment. 
| Strengths and limitations
The SI-ALS is a strictly unidimensional measure which gives the advantage of providing a single linear score of spasticity without a need for subscales. The raw scores provide a truly ordinal measure of spasticity, which can be converted to interval level measurement using the transformation table provided (on the proviso that there are no missing data). This facilitates the use of path analysis, as in the above example.
The measure requires the patient, or their scribe, to tick 20 items with a simple four-level Likert scale. Time and ease of administration of the scale is particularly relevant in ALS patients due to high levels of physical disabilities and fatigue. 23 The scale items reflect patient language and experience, and the cognitive debriefs and validation analysis showed high face validity and patient acceptability.
In particular, participants reported satisfaction that bulbar spasticity was included, because for affected patients, bulbar spasticity was a profound symptom and they deplored its omission from generic measures or those developed for other conditions.
The study also has several limitations. Respondents' spasticity was not clinically assessed by a physician and validated against the SI-ALS. This was considered unnecessary and conceptually inappropriate for several reasons. First, the aim of the SI-ALS was to develop a patient-centred outcome measure, which is based on the patient's experience rather than a clinician's observation of spasticity. As a result, the SI-ALS and clinical assessment should be viewed as complementary rather than competing measures of spasticity. Secondly, previous studies have demonstrated that agreement between clinician-administered methods and patient report of spasticity is poor (r < .5) indicating that clinician's assessment is by no means a "gold-standard" measure. 
| Future directions
The present study serves as a platform for further research into the complex interplay between spasticity, physical and psychosocial factors and quality of life in ALS. Given interval-level data, the SI-ALS provides an opportunity for advanced statistical modelling of quality 
| CON CLUS ION
The SI-ALS is a brief and reliable patient reported outcome measure of spasticity designed for use by people with ALS. Its development is based on ALS patient experience of spasticity and is in line with the Food and Drug Agency (FDA) guidelines for scale development. 24 Given the scale satisfies the requirements of Rasch measurement, the SI-ALS provides an interval level measurement of spasticity, which is valid for parametric analysis. The scale has high reliability and can be used in all patients with ALS irrespective of age, sex, disease duration and type. It is free for use for academic users and non-profit organizations and can be obtained via contact with the authors.
